

## Instructions for Contributors

### GENERAL INFORMATION

Papers are accepted for consideration on the condition that they are contributed solely to this journal. Papers reporting human experimentation will be reviewed in accordance with the precepts established in the Helsinki Declaration. Copies of this declaration may be obtained by writing to the American Medical Association, 535 North Dearborn Street, Chicago, Illinois. Manuscripts and all communications concerning editorial matters should be addressed to *Frederick Stohlman, Jr., M.D., St. Elizabeth's Hospital, 736 Cambridge Street, Brighton, Massachusetts 02135.*

### MANUSCRIPTS

Manuscripts must be typewritten, in good English, double or triple-spaced on good quality paper with margins of at least one inch. The *original and one complete copy* of the manuscript must be submitted.

#### First Page

The first page of the manuscript should contain the following information:

- (1) Title of the paper
- (2) Authors' names
- (3) Authors' affiliations
- (4) Name of the institution in which the work was done
- (5) Acknowledgments for research support which the authors wish to have published.
- (6) *Name and address of the authors to whom communications regarding the manuscript should be directed.*

#### Abstract

The second page should contain an abstract which, in general, should be less than 200 words. The abstract should summarize the reason for the study, the methods used, the results, and the major conclusions. Do *not* include a summary at the end of the paper.

The remainder of the manuscript should be written as concisely as possible. Only *essential* references should be cited.

### TABLES AND ILLUSTRATIONS

Tables and illustrations should be critically evaluated so that information contained therein is not duplicated. Only those *which are essential* for a clear presentation of the data should be included.

Each table should be typed on a separate sheet and appropriately numbered. Legends should be typed on the same sheets as the tables.

Diagrams, charts and other line drawings should be submitted as glossy, black-and-white photographs. These must be submitted in duplicate, but clearly legible copies may be used with the duplicate manuscript. Lettering, symbols, lines, and strippling must be clear and distinct, and the

effect of possible reduction in size to fit the printed page should be considered. Each figure must be identified by number and author's name written lightly with pencil on the back, and the top of the illustration should be indicated.

Photomicrographs and other photographic illustrations must be submitted in duplicate; copies are not acceptable.

Legends for illustrations should be typewritten, double-spaced, on a separate sheet.

Tables in excess of one and one-half printed pages total will be charged for at approximately \$80.00 per page. Illustrations in excess of four are charged for at \$25.00 each. The cost of colored illustrations in both articles and reprints must be borne by the contributor, and an estimate of such cost will be provided by the publisher after acceptance of the material.

### REFERENCES

References should be compiled numerically according to the order of citation in the text. They should be typewritten, double-spaced under the heading REFERENCES. See examples below. Note use of the paragraph indentation. Do not underline or use all capitals. Use initials for the names of cited authors rather than full first names. The abbreviation, "et al.," is permitted in text but not in lists of references.

Abbreviations for titles of medical periodicals should conform to those used in *Index Medicus*. (A "List of Journals Indexed in Index Medicus"—with abbreviations—is obtainable from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, at a modest charge.) Note that BLOOD uses periods for such abbreviations. Abbreviate publishers' names by elimination of their initials and such designations as "Company, Inc., Bros., Ltd."

If the original language of a foreign-language title uses other than the Roman alphabet, give the title in English, followed by a parenthetical note—e.g. (in Russian). Other foreign-language titles should be given in the original language.

In the examples below note the order of material, style of punctuation, the different use of capital letters for book and journal literature, and the use of Ed. (editor) and ed. (edition).

Before submitting the final draft, check the numbering and spelling of authors' names in the list of References against the form used in the text.

#### Examples

BOOK (cite the exact page only if necessary; note handling of "edition"):

1. Allen, A. C.: The Kidney—Medical and

(Continued on reverse side)

Surgical Diseases (ed. 2). New York, Grune & Stratton, 1962, p. 147.

JOURNAL ARTICLE (cite only first page of article, not inclusive pages):

2. Smith, G. F., Kolb, H., and Faunch, J. A.: Spindle bridge and mid-body in cultured lymphocytes. *Blood* 31: 175, 1968.

CONTRIBUTION TO BOOK (note handling of "Editors" and "Volume"):

3. Luetscher, J. A., and Cheville, R. A.: Measurement of secretion rates of adrenal cortical hormones. In Astwood, E. B., and Cassidy, C. E. (Eds.): *Clinical Endocrinology*, Vol. II. New York, Grune & Stratton, 1968.

#### PROOFREADING

Contributors are provided with galley proofs

and are asked to proofread them for typesetting errors. Important changes in data are allowed within reason without cost, but excessive alterations and additions must be charged to the contributor.

#### LETTERS TO THE EDITOR

Letters to the Editor are welcomed and will be published if appropriate. They should be typewritten double-spaced and, generally, should not be more than 2 typewritten pages in length.

#### ANNOUNCEMENTS

Announcements of meetings, conferences and the like which are of interest to the readership of *Blood* should be sent to the Editor at least 8 weeks before the first day of the month of issue. These items should be as concise as possible.

### Index to Advertisers

November 1971

**ABBOTT Scientific Products Division**  
Antihemophilic Factor ..... xv

**Ames Company**  
Hema-Tek ..... xiii

**BIOTEST-Serum-Institut, Ffm.**  
Testing Serums ..... iii

**British Medical Journal**  
Journal of Clinical Pathology ..... xvi

**Burroughs Wellcome & Co. (U.S.A.) Inc.**  
Zyloprim ..... x-xi  
Anti-Leukemia ..... 3C

**Clay Adams**  
Sero-Fuge/Sero-Liner ..... 2C

**Grune & Stratton, Inc.**  
*Advances in Nuclear Medicine*,  
Lawrence, ed. .... xvii  
*Diagnosis and Treatment of Multiple*  
*Myeloma*, Walsenstrom ..... xxiii  
*Hemopoietic Cellular Proliferation*,  
Stohlman ..... xxxiii  
*Immunopathology*, Miescher ..... xxiv

**Hyland (Division Travenol**  
**Laboratories, Inc.)**  
Austigen ..... viii-ix

**Kalmedic Instruments, Inc.**  
Fragiligraph ..... xxiv

**Ortho Diagnostics**  
Institutional ..... 4C  
Blood Bank ..... xix-xx

**Roche Laboratories (Division of**  
**Hoffmann-LaRoche, Inc.)**  
FUDR ..... vi-vii

**Ivan Sorvall, Inc.**  
RC-3 Centrifuge ..... xviii

**Technicon Instruments Corp.**  
Hemalog/Hemalog D ..... v

**Charles C Thomas, Publishers** ..... xii

## DON'T READ THIS AD

(If you're not interested in RBC or WBC

# osmotic fragility

or Platelet Aggregation)

In just 3½ minutes, the Fragiligraph records and measures the fragility of erythrocytes. In just 7 minutes, the Fragiligraph records and measures the fragility of leukocytes. Additionally, an adaptor is being made available which determines platelet aggregation—eliminating the need for a separate costly instrument for this procedure alone.

All completely automatic, all measured in minutes, all read at a glance. And all in one instrument, the Fragiligraph.

In present use at an impressive array of clinical and research centers, the Fragiligraph is now recognized as a valued adjunct in such broad spectrum areas as: *Blood Preservation and Survival, Pediatrics, Oncology; Radiation, Pressurization, Kidney Dialysis; Mechanical Trauma and Toxicological Studies*, among others.

For elaborated details on the above, write to us and receive all 35 of the published current literature.



Unless you're not interested in rapid automated tests for RBC or WBC osmotic fragility. Or platelet aggregation. And haven't read this ad.

**KALMEDIC** INSTRUMENTS, INC.  
SUBSIDIARY OF KALVEX, INC.  
425 PARK AVENUE NEW YORK CITY 10022

This new text is the result of the proceedings of a symposium jointly prepared by the WHO Immunology Unit and the International Immunopathology Committee.

The text presents discussions by international authorities on the latest developments in immunopathology and their significance to the efforts of alleviating international health problems.

In view of the important findings taking place in many biomedical fields, five different subjects were reviewed: cell interaction and recognition as involved in research of the basic mechanism of immunization; the control of antibody synthesis and immunoglobulin deficiency diseases; immune mechanisms of inflammation and injury; tissue specific immunopathology; and viral immunopathology.

approx. 475 pp., \$26.00

## IMMUNOPATHOLOGY

ANTIGEN CELL INTERACTION  
AND THE CONTROL OF  
ANTIBODY SYNTHESIS

6th International Symposium

EDITED BY PETER A. MIESCHER, M.D.

**GRUNE & STRATTON, INC.**

111 FIFTH AVENUE, NEW YORK, N.Y. 10003

---

## GRUNE & STRATTON

111 Fifth Avenue, New York, N.Y. 10003

### DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA

by JAN WALDENSTROM, M.D.

FROM J.A.M.A.—

"When we approach this monograph authored by a brilliant clinical investigator who has contributed fundamental information on immunoglobulins, our expectations understandably run high—and they are not disappointed."

"The exposition combines thorough bedside and laboratory study of 140 patients with multiple myeloma, and a highly critical evaluation of pertinent world literature."

". . . a comprehensive picture emerges of the disease, encompassing incidence, cytologic, hematologic, roentgenologic features, and clinical symptoms and course."

"The book offers much more than promised in the title. Many fascinating aspects are brought to the reader's attention, such as recent changes in the sex distribution; the possible role of ionizing radiation in the etiology of the disease; frequent coexistence of multiple myeloma with lymphocytic leukemia or reticulum cell sarcoma; differences and transitions between monoclonal and polyclonal gammopathies; relationship between abnormal serum globulins and impairment of immune functions."

"Clinicians may particularly enjoy the thorough discussion of pathogenesis and management of amyloidosis, hypercalcemia, and uremia in patients with multiple myeloma."

240 pp., 54 illus., \$15.00

### HEMOPOIETIC CELLULAR PROLIFERATION

Edited by  
FREDERICK STOHLMAN, JR., M.D.


This book contains the edited proceedings of a Conference on Hemopoietic Cellular Proliferation, held at St. Elizabeth's Hospital in Boston.

Its purpose is to provide an in-depth study of the important physiologic facts and concepts, and to consider these findings in the light of the many diseases of hemopoiesis which are seen in the clinic. The reader is afforded a clear understanding of the complicated cellular interrelationships as well as insight into the mechanism of control of cell production under normal conditions and after increased physiologic demand.

The hematologist and pathologist and interested physicians as well as investigators of cellular proliferation will find this book rewarding reading—as a compendium of current knowledge of the physiology of the bone marrow and its relationship to clinical disease and as a valuable reference work.

352 pp., 143 illus., \$19.75

---



Even back in the 1890's, Sir Henry S. Wellcome had it. First, to pioneer in pharmaceutical research. Later, in 1936, to provide in his will for expanding research. Current researchers at Burroughs Wellcome also have it. Continuing in Sir Henry's tradition, we have developed: Purinethol® mercaptopurine tablets 50 mg., Daraprim® pyrimethamine tablets 25 mg., Imuran® azathioprine tablets 50 mg. and Zylprim® allopurinol tablets 100 mg.

Burroughs Wellcome Co. markets many products to help you in medicine. Consider these, for example:

**IMURAN®** tablets  
50 mg.  
(azathioprine)

**ALKERAN®** tablets  
2 mg.  
(melphalan)

**LEUKERAN®** tablets  
2 mg.  
(chlorambucil)

**MYLERAN®** tablets  
2 mg.  
(busulfan)

**PURINETHOL®** tablets  
50 mg.  
(mercaptopurine)

**THIOGUANINE  
TABLOID®** tablets 40 mg.



**Wellcome**

**BURROUGHS WELLCOME CO.**

Research Triangle Park, North Carolina 27709

Complete literature available on request from Professional Services Dept. PML.



extensive quality through intensive research



ORTHO DIAGNOSTICS

Raritan, New Jersey 08869

© O. D. 1988